Orchestra BioMed Holdings, Inc. (OBIO) stock
OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$7.00−0.46 (-6.17%)
Close on Nov 19, 2026Market cap $420.74MP/E –Yield –
Orchestra BioMed free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Orchestra BioMed's free cash flow for the twelve months ending Jun 30, 2026 was -$59.10M. For fiscal 2025 it was -$49.45M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.45M | – |
| FY2024 | Dec 31, 2024 | -$50.85M | – |
| FY2023 | Dec 31, 2023 | -$46.21M | – |
| FY2022 | Dec 31, 2022 | -$29.88M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.64M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.37M | – |
See a number that looks wrong?